Biotech roars, AI chips refuse to cool, and the tape rewards risk again
Risk appetite came back with a grin on Friday. Biotech ripped higher, AI semis held court, and short interest added petrol. Meanwhile, investors treated macro noise as background music, as long as revenues and guidance kept moving.
ImmunityBio, ticker IBRX, was the day’s clearest pressure cooker. The shares jumped about 6% to roughly $8.32, pushing the company towards a $7 billion market value. That move followed a quarter that traders will not forget quickly. Revenue rose by roughly $44 million, while the stock logged a headline-grabbing 287% quarterly surge.
However, the story is not only momentum. ImmunityBio’s cancer therapy Anktiva is now cleared across 33 countries, including the EU’s 27. That kind of regulatory perimeter tends to change how fast a biotech can sell, hire, and fund trials. Therefore, the market started to price in a more durable commercial ramp, not just another hopeful pipeline name.
Then there is positioning. Short interest sits near 43%. Borrow fees have been quoted around 141%. In plain English, bearish bets are expensive to carry, and they can turn into forced buying quickly. Meanwhile, sell-side chatter has floated $14 to $15 targets. Those numbers do not move a stock by themselves. Yet they can anchor intraday narratives, especially when the borrow is tight.
Broadcom, ticker AVGO, played the other half of the day’s script. The company posted quarterly earnings that kept the AI chip trade in motion. Earnings per share printed at about $2.05, above a cluster of expectations around $1.88 to $2.03. More importantly, AI demand again did the heavy lifting, and the market treated any wobble as a buy-the-dip invitation. However, the stock’s premium multiple means perfection stays priced in. That raises the cost of bad news later.
On the macro side, retail sales were strong, up about 1.7%. The Dow added roughly 200 points, or 0.48%. Therefore, cyclicals found friends again. Yet the more interesting action sat in single names where beats, raises, and positioning could spark quick extensions.
NetSTREIT, ticker NTST, drew income-focused attention after an earnings beat and a lift to its full-year outlook. Meanwhile, regional banks kept flashing tradable setups. Zions, ticker ZION, benefited from its own earnings momentum and higher price targets floating around $63+, which can act like a magnet in a strong tape. However, regional banks remain headline-sensitive, and the stops need to match that reality.
A few other pockets stood out. Plug Power, ticker PLUG, showed relative strength by holding steady while other industrial names sagged. AXT, ticker AXTI, faced dilution headlines after a large offering, which can create ugly first reactions and decent bounce conditions if panic exhausts itself. Elsewhere, some crowded or overheated names looked ready for the other side of volatility, including BB, MXL, and ADTN, where stretched RSI readings often invite sharp pullbacks.
By the numbers
- IBRX: up about 6% to roughly $8.32, market cap near $7bn.
- Anktiva: cleared across 33 countries, including the EU 27.
- IBRX: short interest near 43%, borrow fees quoted around 141%.
- AVGO: EPS about $2.05 versus expectations around $1.88 to $2.03.
- Retail sales: about +1.7%; Dow about +0.48%.
Key takeaways
- IBRX has a classic squeeze profile, so size small and respect fast reversals.
- AVGO remains the AI quality bid, yet any guide wobble can punish premium multiples.
- REIT beats like NTST can run in bursts, especially when rates behave for a week.
- Regional banks can trend on upgrades, but headline gaps still rule risk management.
- Overbought fades work best when the broader index stops making new highs.
